This international clinical trial is enrolling an estimated 1,224 participants who have been diagnosed with type 2 diabetes, age 18 or older. This study is...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
33 readers recommended
How one clinic is integrating diabetes and heart health, focusing on comprehensive risk reduction, including medications that both lower blood glucose and protect the...
37 readers recommended
In this clinical trial, researchers are studying the effectiveness of dapagliflozin and saxagliptin in children and adolescents with type 2 diabetes. While these drugs...
69 readers recommended
When it comes to SGLT-2s and GLP-1s, there are several medicines available. Read below for more information on these therapies which have particular benefits for those...
61 readers recommended
The Association of Diabetes Care and Education Specialists 2021 conference covered the impacts of diabetes stigma, smart MDI therapies, insulin delivery by means other...
31 readers recommended
Learn about anti-CD3 therapy designed to slow or stop the progression of type 1 diabetes.
34 readers recommended
Juvenile Diabetes Research Foundation President and CEO Dr. Alan Lewis discusses the organization's priorities, one year in.
27 readers recommended
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
46 readers recommended
Novo Nordisk’s once daily GLP-1 agonist Victoza (above) provided slightly better improvements in blood glucose control than Amylin/Eli Lilly/ Alkermes’s once weekly GLP-...
37 readers recommended
A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).
38 readers recommended
Last week, in a surprise and, in our view, disappointing move, the FDA decided to not approve Bydureon, a once-weekly GLP-1 agonist, for use in the United States despite...
44 readers recommended
For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta ) can often lead to significant improvements in blood glucose control and weight loss with...
28 readers recommended
A girl can dream, right? (...of cures and new insulins...)
43 readers recommended
David Simmons, President and General Manager of Pfizer’s Established Products Business Unit, and Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon, shake...
26 readers recommended
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
29 readers recommended
We recently reviewed three drug candidates for the treatment of obesity – Contrave, lorcaserin, and Qnexa. All three drugs in development: they all have been submitted...
43 readers recommended
After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...
40 readers recommended
Earlier this month, the FDA approved the once-daily oral drug Tradjenta (Boehringer Ingelheim and Eli Lilly’s linagliptin) for type 2 diabetes. Tradjenta belongs to the...
39 readers recommended
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
27 readers recommended
In mid-November, Santarus Inc. announced the launch of Cycloset, a novel, weight-neutral, glucose-lowering drug for type 2 diabetes. Cycloset is a quick-release...